Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Atypical Antipsychotics

Posted by Matt Breese on Nov 14, 2016

Find me on:

According to our recent payer coverage analysis for atypical antipsychotic treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A look at market access over the past two quarters shows that restricted lives in the health exchange and commercial channels increased greatly.

reality-check-antipsych-atypical.png

Source: MMIT data as of Q4 2016

Trends:  Recent news related to antipsychotic treatments shows an increasing attention to prescribing habits. With atypical antipsychotic prescriptions for child patients increasing, clinicians call for more safety and efficacy trials for adolescent patients. Additionally, recent research shows that antipsyschotic manufacturers are connecting to prescribers via social media.

In the full Reality Check on antipsychotic treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on atypical antipsychotics with key findings on clinical characteristics, antipsychotic drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

 

Topics: Specialty, Market Access, Branding & Marketing